LEO Pharma scientists win Innovator of the Year 2019 Award from Innovation Fund Denmark

Ballerup, Denmark, 1 February, 2019 – LEO Pharma, a global leader in medical dermatology, today announced that two of the company's scientists have been awarded Innovation Fund Denmark's Innovator of the Year Award 2019.

Focus for the Innovator of the Year Award 2019 is on ‘excellent and groundbreaking research which creates value for Denmark’ - based on the following assessments:

  • The value the candidates have created for patients as well as business
  • The candidates' ability to translate excellent research knowledge into tangible solutions

Marianne Lind, Ph.d., Senior Scientist and Karsten Petersson, Ph.d., Director, both at LEO Pharma, received the Award for the development of Enstilar®, LEO Pharma's foam spray for the treatment of plaque psoriasis. Enstilar® was approved by the Danish Medicines Agency and launched in Denmark in 2016, and more than one million patients use the product today.

The Innovator of the Year Award 2019 was presented by Minister of Education and Research Tommy Ahlers at a ceremony in Copenhagen, together with the Innovation Fund's vice-chairman, Anja Boisen. In addition to the Award, the winners receive DKK 100,000 each.

In a press release from Innovation Fund Denmark, Minister of Education and Research Tommy Ahlers said:

"The projects you (LEO Pharma) have created are innovative and exciting, they are built upon world class research and we need that. Your achievements make a difference to our society. You are an inspiration to others – use it to be role models for the next generation of researchers. Congratulations on your ability and willingness to create something new – and congratulations on the Awards."

In his speech to the Awards winners Danish Minister of Education and Research Tommy Ahlers said, among others:

"With their innovative ideas and inspirational research, this year's Award winners help to change our society and the way we live. With knowledge, courage and commitment, they have created strong results and value for citizens, companies and our entire society, which ultimately helps put Denmark on the world map. It is this fantastic achievement we are celebrating today," says Peter Høngaard Andersen, Director, Innovation Fund Denmark, in the same press release.

"We are very proud and very grateful to receive this year's Innovator Prize. It is a fantastic – and well–deserved – recognition of the great and dedicated work that every LEO Pharma's many hundred scientists do every day. Not least because it illustrates in the best possible way how we work purposefully with innovation in LEO Pharma to develop new, groundbreaking dermatological treatments that can help make life easier for the many millions of patients worldwide living with skin diseases. "Says Kim Kjøller, Executive Vice President, LEO Pharma.

It is the third consecutive year that Innovation Fund Denmark presents its annual awards which, in addition to the Innovator of the Year Award, include the Grand Solutions Award and the Industrial Researcher Award.

 

About Innovation Fund Denmark

Innovation Fund Denmark (IFD) was established in April 2014. The purpose of ITD is to fund advances in science and technology, including advanced technology, in order thereby to boost research and facilitate innovative solutions for the benefit of growth and employment in Denmark. IFD focuses on funding solutions to specific societal challenges and strengthen private sector research and innovation initiatives in small and medium–sized enterprises.

About LEO Pharma

LEO Pharma helps people achieve healthy skin. The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is head-quartered in Denmark with a global team of 5,700 people, serving 80 million patients in 130 countries. In 2017, the company generated net sales of euro 1.4 billion.

For more information, go to: www.linkedin.com/company/leo-pharma 

We use cookies on this website

The cookies help us gain a better understanding of how you use our website; display applications and functionalities, to optimise your website experience, to assign a unique identification number to you, and to help you remember your user ID and password when you return to the website. We also use cookies to generate statistical information.

By continuing to browse our website, you are agreeing to our use of cookies

If you want to know more about our cookie policy and how to avoid and delete cookies click here.